Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc. (NASDAQ: NUVL) filed a Form 8-K covering two corporate-governance items dated June 18, 2025.
Board change (Item 5.02): The Board unanimously elected Christy J. Oliger as an independent Class III director, effective immediately. She will serve until the 2027 annual meeting and join the Audit Committee. Compensation aligns with the existing non-employee director policy and includes:
- Initial stock option for 6,119 shares at an exercise price of $75.53, vesting monthly over three years.
- Initial RSU award of 3,971 shares, vesting annually over three years.
- Annual cash retainers and ongoing equity grants as stipulated in the policy.
2025 Annual Meeting results (Item 5.07): Quorum was strong with 64.38 million votes representing 97.01 % of outstanding shares. Outcomes were:
- Director elections: Grant Bogle (99.87 % support); James R. Porter, Ph.D. (99.78 %); Anna Protopapas (86.27 %).
- Say-on-pay: Approved with 83.8 % (53.52 m for, 10.36 m against).
- Auditor ratification: KPMG LLP re-approved with 99.98 % support.
Investor take-away: The filing is largely procedural. The addition of an experienced independent director strengthens oversight, while voting results confirm broad shareholder support for existing leadership and compensation structure.